KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Cash from Financing Activities for 16 consecutive years, with $45.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 46.2% year-over-year to $45.3 million, compared with a TTM value of -$305.2 million through Dec 2025, down 203.75%, and an annual FY2025 reading of -$305.2 million, down 203.75% over the prior year.
  • Cash from Financing Activities was $45.3 million for Q4 2025 at Alnylam Pharmaceuticals, up from -$448.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $573.8 million in Q3 2021 and bottomed at -$448.3 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $91.7 million, with a median of $48.8 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities soared 1580.5% in 2021, then tumbled 536.33% in 2025.
  • Year by year, Cash from Financing Activities stood at $292.3 million in 2021, then plummeted by 78.3% to $63.4 million in 2022, then tumbled by 38.16% to $39.2 million in 2023, then dropped by 20.98% to $31.0 million in 2024, then surged by 46.2% to $45.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ALNY at $45.3 million in Q4 2025, -$448.3 million in Q3 2025, and $53.8 million in Q2 2025.